바카라 꽁 머니 to raise KRW 30 billion via paid-in capital increase to boost novel drug development and business diversification

[by Kang, In Hyo] 바카라 꽁 머니 announced on August 19 that it will raise KRW 30 billion (approximately USD 25 million) through a shareholder-allotted paid-in capital increase. The company plans to direct the funds toward accelerating the commercialization of its core pipeline.

This paid-in capital increase will be carried out through a ‘shareholder allocation followed by a forfeited share offering,’ with securities firms set to underwrite the total number of unsubscribed shares. Shaperon plans to issue 16.1 million new shares at an expected price of KRW 1,866 per share.

Funds will be allocated primarily to global Phase 2 clinical trials for the atopic dermatitis treatment candidate, domestic Phase 1 trials for Alzheimer's disease and pulmonary fibrosis, additional pipeline 바카라 꽁 머니, including a treatment for alopecia areata, 바카라 꽁 머니 of a NanoMab-based immuno-oncology candidate, and entry into new healthcare businesses in Korea and international markets.

바카라 꽁 머니's atopic dermatitis treatment candidate is currently in a global Phase 2, Part 2 clinical trial in the U.S., with completion expected in H1 2026 following the encouraging Phase 1 trial results. Its Alzheimer's disease and pulmonary fibrosis treatment candidates are also on track to wrap up Phase 1 trials in Korea during the same period. The company explained that development of its AI-driven alopecia areata candidate is progressing rapidly, with preclinical studies showing strong efficacy.

Previously ranked among the world’s top 10 developers of inflammatory complex inhibitors, Shaperon stands out as the only company developing a therapy targeting GPCR19, a distinction that has drawn strong interest from global pharmaceutical players in the inflammation market.

바카라 꽁 머니 noted that the successful completion of the Phase 2, Part 1 trial for the atopic dermatitis treatment candidate earlier this year has been seen as a positive development for the inflammatory complex field, which has struggled to deliver clinical successes despite multi-billion dollar technology deals.

Shaperon's immuno-oncology candidate, ‘papiliximab,’ is the world's first bispecific antibody built on NanoMab technology. According to the company, in preclinical monkey studies funded by the Korea Planning & Evaluation Institute of Industrial Technology (KEIT), the therapy showed a marked reduction in anemia, a major side effect that has hindered rival’s programs, significantly boosting its prospects for clinical success. The breakthrough has drawn increasing attention from the market.

Globally, developers are intensifying competition in the bispecific antibody market, an arena valued in the tens of trillions of won, even as hundreds of antibody therapeutics have already been approved. Yet technological hurdles remain steep, with fewer than 20 bispecific antibodies approved to date.

Shaperon has addressed competitors’ development hurdles with its ‘NanoMab’ platform, a bispecific antibody just one-tenth the size of conventional formats. The company sees this as a potential ‘game-changer,’ noting that no NanoMab-based bispecific antibody has yet received regulatory approval.

바카라 꽁 머니 is reinforcing its path to commercialization by filing and securing related patents in major global markets. Up to date, leading international institutions have begun approaching it with co-development proposals for NanoMab-based multi-antibody therapies.

In its healthcare business, Shaperon this year announced its entry into the ‘inflammation aging’ market, leveraging its inflammasome inhibition technology. Currently, the company has already registered one raw material with the International Cosmetic Ingredient Dictionary and Handbook (ICID) and is in the process of registering four more. To accelerate product launches, Shaperon is also bringing in seasoned industry experts.

"This paid-in capital increase is a strategic move aimed at strengthening the company's short-term financial stability by successfully completing clinical trials of existing treatments, developing its next-generation NanoMab bispecific antibody, and accelerating growth in its healthcare business. Our goal is to shorten the timeline to commercialize novel drug technologies and establish a virtuous growth cycle supported by stable cash flow," a Shaperon official stated.

"This capital increase will take our key pipelines, which we have been under R&D for the past 20 years, a step closer to early commercialization," said Sung Seung-yong, CEO of Shaperon. "We also anticipate a significant improvement in the company's financial structure, and we are fully committed to participating in this capital increase."

"Although this strategic decision was made with the company's future in mind, we sincerely apologize for any inconvenience it may cause to shareholders. Together with our employees, we will work tirelessly to deliver outstanding results in return," Sung further remarked.